Companies Cryptocurrencies
Vir Biotechnology Inc
Vir Biotechnology Inc
Exchange: NasdaqGS
IPO Date: 11/10/2019
CEO: Dr. George Scangos
Biotechnology Healthcare 🔗
  • VIR
  • 30.65
  • 4057324288
    market cap
  • 1.8099995
If you bought

shares of Vir Biotechnology Inc (VIR) on
You would have made
Old Price $12 Current Price $12

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California and currently employs 217 full-time employees. The firm is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and tuberculosis (TB). Its product candidates include VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-2020. The firm is developing VIR-2218 and VIR-3434 for the functional cure of HBV. VIR-2218 is a subcutaneously administered HBV-targeting siRNA. VIR-3434 is a subcutaneously administered HBV-neutralizing monoclonal antibody (mAb). VIR-2482 is an intramuscularly administered influenza A-neutralizing mAb. VIR-1111 is a subcutaneously administered HIV T cell vaccine. VIR-2020 is a subcutaneously administered TB T cell vaccine.

Address: 499 Illinois St Ste 500 San Francisco CALIFORNIA 94158

Stay updated.